Investigational Drug Information for CC-220
✉ Email this page to a colleague
What is the development status for investigational drug CC-220?
CC-220 is an investigational drug.
There have been 28 clinical trials for CC-220.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 15th 2023.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.
There are twenty-nine US patents protecting this investigational drug and two hundred and eighty international patents.
Summary for CC-220
| US Patents | 29 |
| International Patents | 280 |
| US Patent Applications | 131 |
| WIPO Patent Applications | 71 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 2 (2023-06-15) |
| Vendors | 41 |
Recent Clinical Trials for CC-220
| Title | Sponsor | Phase |
|---|---|---|
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | National Cancer Institute (NCI) | Phase 2 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Bristol-Myers Squibb | Phase 3 |
Clinical Trial Summary for CC-220
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
US Patents for CC-220
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CC-220 | ⤷ Sign Up | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | Celgene Corporation (Summit, NJ) | ⤷ Sign Up |
| CC-220 | ⤷ Sign Up | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione | Celgene Corporation (Summit, NJ) | ⤷ Sign Up |
| CC-220 | ⤷ Sign Up | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Celgene Corporation (Summit, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-220
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CC-220 | Australia | AU2015305449 | 2034-08-22 | ⤷ Sign Up |
| CC-220 | Australia | AU2021209158 | 2034-08-22 | ⤷ Sign Up |
| CC-220 | Brazil | BR112017003620 | 2034-08-22 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
